Company intelligence / Profile preview
AmacaThera
Toronto, Ontario, Canadaamacathera.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
The lead product, AMT‑143, combines an anesthetic with AmacaThera’s proprietary hydrogel to provide sustained post-surgical pain relief. Early clinical results are pending; the goal is opioid-sparing analgesia lasting up to 72 hours after surgery. The company’s technology has not previously been tested in humans and represents a novel approach to local drug depot formation and controlled release. Additional programs are preclinical or exploratory.
- Therapeutic areas
- OncologyNeurology
- Modalities
- Injectable hydrogel-based drug deliverycombination with small molecules (e.g., anesthetics)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Research Institute of St. Joseph’s Healthcare Hamilton [for health economic impact studies on non-opioid postoperative pain products].
Beyond the preview
Go deeper on AmacaThera.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AmacaThera.